138786-86-4

Usage

Uses

Used in Organic Synthesis:
1H-Pyrazole-3-carboxylic acid, 4-nitro-, methyl ester is utilized as a key intermediate in organic synthesis for the preparation of various complex organic molecules. Its unique structural features allow for the construction of diverse chemical entities, facilitating the development of novel compounds with potential applications in different fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1H-Pyrazole-3-carboxylic acid, 4-nitro-, methyl ester is employed as a building block for the synthesis of new drug candidates. Its incorporation into drug molecules can potentially enhance their therapeutic properties, such as improving pharmacokinetics, bioavailability, and target selectivity.
Used in Agrochemical Development:
1H-Pyrazole-3-carboxylic acid, 4-nitro-, methyl ester also finds application in the agrochemical sector, where it serves as a precursor for the development of new pesticides and herbicides. Its chemical properties enable the creation of agrochemicals with enhanced efficacy and selectivity, contributing to more effective crop protection strategies.
Used in Anti-Cancer Research:
1H-Pyrazole-3-carboxylic acid, 4-nitro-, methyl ester is studied for its potential anti-cancer properties, with the aim of identifying its role in inhibiting tumor growth and progression. Its incorporation into anti-cancer drug development may lead to the discovery of novel therapeutic agents with improved efficacy and reduced side effects.
Used in Anti-Inflammatory Studies:
1H-Pyrazole-3-carboxylic acid, 4-nitro-, methyl ester is also being investigated for its anti-inflammatory potential, which could be beneficial in the treatment of various inflammatory conditions. Its ability to modulate inflammatory pathways may pave the way for the development of new anti-inflammatory drugs with better safety profiles and therapeutic outcomes.

Upstream product

• 67-56-1 methanol 
• 5334-40-7 4-nitro-1H-pyrazole-3-carboxylic acid 
• 5334-40-7 4-nitro-1H-pyrazole-5-carboxylic acid 
• 75-36-5 acetyl chloride 
• 7719-09-7 thionyl chloride 

Downstream Products

• 138786-90-0 1-((2R,3R,4R,5R)-3,4-Bis-benzoyloxy-5-benzoyloxymethyl-tetrahydro-furan-2-yl)-4-nitro-1H-pyrazole-3-carboxylic acid methyl ester 
• 400877-57-8 1-methyl-4-nitro-1H-pyrazole-3-carboxylic acid methyl ester 
• 637336-53-9 4-amino-1-methyl-1H-pyrazole-3-carboxylic acid methyl ester 
• 923283-54-9 methyl 4-amino-1-methyl-1H-pyrazole-5-carboxylate 
• 869299-53-6 methyl 1-[2-({4-[(methyloxy)carbonyl]phenyl}oxy)ethyl]-4-nitro-1H-pyrazole-5-carboxylate 
• 869299-54-7 methyl 1-[2-({4-[(methyloxy)carbonyl]phenyl}oxy)ethyl]-4-nitro-1H-pyrazole-3-carboxylate 
• 309740-49-6 methyl 1-methyl-4-nitro-1H-pyrazole-5-carboxylate 
• 1021498-07-6 4-(2-bromoacetylamino)-1-phenethyl-1H-pyrazole-3-carboxylic acid methyl ester 
• 1021498-06-5 4-amino-1-phenethyl-1H-pyrazole-3-carboxylic acid methyl ester 
• 1452128-21-0 4-[2-(4-bromophenoxy)acetylamino]-2-phenethyl-1H-pyrazole-3-carboxylic acid methyl ester 
• 1452128-20-9 4-[3-phenylpropionylamino]-2-phenethyl-1H-pyrazole-3-carboxylic acid methyl ester 
• 637336-55-1 1-methyl-4-(trityl-amino)-1H-pyrazole-3-carboxylic acid methyl ester 
• 923283-58-3 methyl?4-amino-1-ethyl-1H-pyrazole-3-carboxylate 
• 923283-30-1 methyl 1-ethyl-4-nitro-1H-pyrazole-3-carboxylate 

Relevant academic research and scientific papers

2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES

The present invention relates to derivatives of formula (I) wherein Ring A, X, Y, Z, RA, R1, R2, R3 and R4 are The present invention discloses derivatives of formula (I), wherein Ring A, X, Y, Z, RA, R1, R2, R3 and R4 are as described in the description, and in particular e.g. 2,4,6,7-tetrahydro-pyrazolo[4,3- d]pyrimidin-5-one derivatives and related compounds, their preparation, pharmaceutically acceptable salts thereof, their use as pharmaceuticals, pharmaceutical compositions containing one or more compounds of formula (I), and especially their use as C5a receptor modulators for treating e.g. vasculitis and inflammatory diseases.

SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

There is provided a compound of formula (I), wherein L1 to L3, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

2-AZABICYCLO[3.1.1] DERIVATIVES AS ANTAGONISTS OF THE OREXIN-1 AND OREXIN-2 RECEPTORS

There is provided a compound of formula I, wherein L1, R1, R2, R5, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

Design, synthesis and biological evaluation of pyridone–aminal derivatives as MNK1/2 inhibitors

Excessive phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) plays a major role in the dysregulation of mRNA translation and the activation of tumor cell signaling. eIF4E is exclusively phosphorylated by mitogen-activated protein kinase interacting kinases 1 and 2 (MNK1/2) on Ser209. So, MNK1/2 inhibitors could decrease the level of p-eIF4E and regulate tumor-associated signaling pathways. A series of pyridone–aminal derivatives were synthesized and evaluated as MNK1/2 inhibitors. Several compounds exhibited great inhibitory activity against MNK1/2 and selected compounds showed moderate to excellent anti-proliferative potency against hematologic cancer cell lines. In particular, compound 42i (MNK1 IC50 = 7.0 nM; MNK2 IC50 = 6.1 nM) proved to be the most potent compound against TMD-8 cell line with IC50 value of 0.91 μM. Furthermore, 42i could block the phosphorylation level of eIF4E in CT-26 cell line, and 42i inhibited the tumor growth of CT-26 allograft model significantly. These results indicated that compound 42i was a promising MNK1/2 inhibitor for the potent treatment of colon cancer.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

HYDROXYL PURINE COMPOUNDS AND USE THEREOF

Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.

HYDROXYL PURINE COMPOUNDS AND USE THEREOF

Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers or pharmaceutically acceptable salts thereof.

CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY

The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.

P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS

The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R7 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient.

Imidazopyridazine IRAK4 inhibitor, and preparation method and application thereof

The invention belongs to the field of medicines, and especially relates to an imidazopyridazine compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and an applicationof a medicinal composition of the compound or the salt in the treatment of tumors, inflammations, immunity and other diseases. The imidazopyridazine compound is a novel protein kinase IRAK4 inhibitor, and can selectively inhibit IRAK4 and downstream signaling pathways thereof. The compound has the structural formula I.